Prediction of outcome in newly diagnosed myeloma: a meta-analysis of the molecular profiles of 1905 trial patients

[1]  S. Rajkumar,et al.  Next-generation multiple myeloma treatment: a pharmacoeconomic perspective. , 2016, Blood.

[2]  H. Goldschmidt,et al.  Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[3]  M. O'sullivan,et al.  Gain of 1q As a Prognostic Biomarker in Wilms Tumors (WTs) Treated With Preoperative Chemotherapy in the International Society of Paediatric Oncology (SIOP) WT 2001 Trial: A SIOP Renal Tumours Biology Consortium Study , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  H. Goldschmidt,et al.  Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group. , 2016, Blood.

[5]  A. Palumbo,et al.  Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. , 2016, The New England journal of medicine.

[6]  D. Vaux,et al.  Targeting p38 or MK2 Enhances the Anti-Leukemic Activity of Smac-Mimetics. , 2016, Cancer cell.

[7]  H. Goldschmidt,et al.  Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  Gordon Cook,et al.  Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  Gregor Bieri,et al.  β2-microglobulin is a systemic pro-aging factor that impairs cognitive function and neurogenesis , 2015, Nature Medicine.

[10]  Aspire Investigators,et al.  Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma , 2015 .

[11]  Gordon Cook,et al.  APOBEC family mutational signatures are associated with poor prognosis translocations in multiple myeloma , 2014, Nature Communications.

[12]  G. Morgan,et al.  A molecular diagnostic approach able to detect the recurrent genetic prognostic factors typical of presenting myeloma , 2014, Genes, chromosomes & cancer.

[13]  Michael L. Wang,et al.  Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. , 2015, The New England journal of medicine.

[14]  Anna Tramontano,et al.  Cancer-Selective Targeting of the NF-κB Survival Pathway with GADD45β/MKK7 Inhibitors , 2014, Cancer cell.

[15]  M. Kuehl,et al.  Novel inhibitors are cytotoxic for myeloma cells with NFkB inducing kinase-dependent activation of NFkB , 2014, Oncotarget.

[16]  B. Barlogie,et al.  Jumping translocations of 1q12 in multiple myeloma: a novel mechanism for deletion of 17p in cytogenetically defined high-risk disease. , 2014, Blood.

[17]  H. Goldschmidt,et al.  IMWG consensus on risk stratification in multiple myeloma , 2014, Leukemia.

[18]  R. Kyle,et al.  An overview of the progress in the treatment of multiple myeloma , 2014, Expert review of hematology.

[19]  S. Vincent Rajkumar,et al.  Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients , 2013, Leukemia.

[20]  M. Amiot,et al.  The Bcl-2 specific BH3 mimetic ABT-199: a promising targeted therapy for t(11;14) multiple myeloma , 2013, Leukemia.

[21]  R Core Team,et al.  R: A language and environment for statistical computing. , 2014 .

[22]  J. Carpten,et al.  Hypodiploid multiple myeloma is characterized by more aggressive molecular markers than non-hyperdiploid multiple myeloma , 2013, Haematologica.

[23]  G. Morgan,et al.  Long-term Follow-up of MRC Myeloma IX Trial: Survival Outcomes with Bisphosphonate and Thalidomide Treatment , 2013, Clinical Cancer Research.

[24]  G. Morgan,et al.  A TC classification-based predictor for multiple myeloma using multiplexed real-time quantitative PCR , 2013, Leukemia.

[25]  M. Schmidt-Supprian,et al.  A20 and CYLD Do Not Share Significant Overlapping Functions during B Cell Development and Activation , 2012, The Journal of Immunology.

[26]  Sankar Ghosh,et al.  NF-κB, the first quarter-century: remarkable progress and outstanding questions. , 2012, Genes & development.

[27]  G. Morgan,et al.  A novel prognostic model in myeloma based on co-segregating adverse FISH lesions and the ISS: analysis of patients treated in the MRC Myeloma IX trial , 2011, Leukemia.

[28]  G. Morgan,et al.  The clinical impact and molecular biology of del(17p) in multiple myeloma treated with conventional or thalidomide‐based therapy , 2011, Genes, chromosomes & cancer.

[29]  G. Morgan,et al.  Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial , 2011, The Lancet. Oncology.

[30]  C. Harrison,et al.  Evaluation of multiplex ligation‐dependent probe amplification as a method for the detection of copy number abnormalities in B‐cell precursor acute lymphoblastic leukemia , 2010, Genes, chromosomes & cancer.

[31]  G. Morgan,et al.  A compendium of myeloma-associated chromosomal copy number abnormalities and their prognostic value. , 2010, Blood.

[32]  G. Morgan,et al.  The t(14;20) is a poor prognostic factor in myeloma but is associated with long-term stable disease in monoclonal gammopathies of undetermined significance , 2010, Haematologica.

[33]  G. Morgan,et al.  Homozygous Deletion Mapping in Myeloma Samples Identifies Genes and an Expression Signature Relevant to Pathogenesis and Outcome , 2010, Clinical Cancer Research.

[34]  Cheng Li,et al.  Prognostic significance of copy-number alterations in multiple myeloma. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  L. Bruhn,et al.  Promiscuous mutations activate the noncanonical NF-kappaB pathway in multiple myeloma. , 2007, Cancer cell.

[36]  L. Staudt,et al.  Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma. , 2007, Cancer cell.

[37]  G. Ahmann,et al.  Prognostic value of chromosome 1q21 gain by fluorescent in situ hybridization and increase CKS1B expression in myeloma , 2006, Leukemia.

[38]  P. L. Bergsagel,et al.  Molecular pathogenesis and a consequent classification of multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Bart Barlogie,et al.  Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. , 2005, Blood.

[40]  J. Crowley,et al.  International staging system for multiple myeloma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  P. Hinds,et al.  Multiple Functions of D-Type Cyclins Can Antagonize pRb-Mediated Suppression of Proliferation , 2005, Cell cycle.

[42]  Tony Reiman,et al.  In multiple myeloma, t(4;14)(p16;q32) is an adverse prognostic factor irrespective of FGFR3 expression. , 2003, Blood.

[43]  C. Bastard,et al.  Hypodiploidy is a major prognostic factor in multiple myeloma. , 2001, Blood.